Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancer.

MLA

Kerin, Eoin P., et al. “Comparison of the Nottingham Prognostic Index and OncotypeDX© Recurrence Score in Predicting Outcome in Estrogen Receptor Positive Breast Cancer.” Breast (Edinburgh, Scotland), vol. 66, Dec. 2022, pp. 227–35. EBSCOhost, https://doi.org/10.1016/j.breast.2022.11.001.

APA

Kerin, E. P., Davey, M. G., McLaughlin, R. P., Sweeney, K. J., Barry, M. K., Malone, C. M., Elwahab, S. A., Lowery, A. J., & Kerin, M. J. (2022). Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancer. Breast (Edinburgh, Scotland), 66, 227–235. https://doi.org/10.1016/j.breast.2022.11.001

Chicago

Kerin, Eoin P, Matthew G Davey, Ray P McLaughlin, Karl J Sweeney, Michael K Barry, Carmel M Malone, Sami Abd Elwahab, Aoife J Lowery, and Michael J Kerin. 2022. “Comparison of the Nottingham Prognostic Index and OncotypeDX© Recurrence Score in Predicting Outcome in Estrogen Receptor Positive Breast Cancer.” Breast (Edinburgh, Scotland) 66 (December): 227–35. doi:10.1016/j.breast.2022.11.001.